Cdc25 Created 2026-10-14 Updated 2026-10-14
Cdc25 is a protein phosphatase: it removes inhibitory phosphate groups from CDK1, relieving inhibition of an appropriately prepared cyclin B–CDK1 assembly. Its reaction is removal, whereas Wee1 is a protein kinase adding inhibitory modification. Removing the inhibitory sites is different from removing the activating phosphorylation supplied by CAK.[ref]
Cdc25 action on CDK1 must also be distinguished from phosphorylation of Cdc25 itself. In cell-cycle activation feedback, CDK1-dependent regulation promotes Cdc25 activity, which can then activate additional inhibited CDK1. The complete regulatory path can involve intermediates. A histone H1 kinase assay of a mixture reports downstream protein kinase action; assigning its change to Cdc25 requires a perturbation or an independent protein phosphatase assay, rather than interpreting histone H1 labeling as phosphate removal.
CDK1 activity and protein abundance are different observables. A total-CDK1 Western blot estimates protein amount under its calibration and loading assumptions. A phosphosite-specific Western blot asks about a particular CDK1 phosphorylation state. A histone H1 kinase assay asks how much substrate modification occurs under specified assay conditions. Any conversion between them needs a model and suitable controls.
An original counting example stipulates CDK1 molecules, with bound to cyclin B in each of two hypothetical samples. In sample A, bound molecules are activity-permissive and are inhibited; in sample B, are activity-permissive and are inhibited. The other are unbound in both samples. Total CDK1 and bound CDK1 agree, but activity-permissive counts differ fourfold. These are invented counts for bookkeeping, not measured biological populations.
If each activity-permissive molecule contributes the same reaction rate, substrate and ATP remain available, and the assay stays linear in time, a simple illustrative readout is
Here is the recorded signal, is a matched blank signal, is the activity-permissive count, the reaction interval, and a common signal contribution per active molecule per unit time. The corrected signals in the stipulated samples have ratio , although their total protein amounts agree. This is an assay accounting assumption, not an ordinary differential equation for the cell cycle. The no-added-cyclin B baseline in the inspected experiment can itself contain catalytic activity; it need not equal an enzyme-free blank .
Substrate depletion, differing inhibitory conditions or a saturated detector can break the simple proportionality. Comparing samples therefore requires matched reaction intervals, substrate supply, loading and detector response, rather than assuming that brighter histone H1 labeling automatically means more total CDK1.
A CDK1 phosphorylation state identifies modified amino acid residues. Different sites have opposite effects: in studied Xenopus laevis Cdc2, Thr14/Tyr15 are inhibitory, while Thr161 phosphorylation is activating. T denotes a threonine residue, Y a tyrosine residue, and numbers are protein primary structure positions. Do not assume this numbering for every species.[ref]
The 1992 study supplies a useful separation of mechanisms: replacing Thr14, Tyr15 and Thr161 still permitted cyclin B binding, but replacing Thr161 prevented activation of histone H1 phosphorylation. Binding therefore did not suffice for catalytic activity in that preparation. Activating phosphorylation also occurred with catalytically inactive Cdc2, supporting a separate CDK-activating kinase rather than a requirement for intramolecular autophosphorylation.[ref]
Figure 1.
Cyclin B binding and site-specific CDK1 phosphorylation states answer different questions
. Original qualitative schematic for the studied Xenopus laevis Cdc2. All four right-hand boxes contain bound cyclin B; only the green box has activating Thr161 phosphorylation with both inhibitory sites clear. “Inhibitory P present” groups Thr14 and/or Tyr15 modification. Arrows show changes of state, not an obligatory sequence, measured rates, or a complete cell cycle model. Myt1 can add either inhibitory modification; Cdc25 removes inhibitory phosphate groups. Details.
In this deliberately coarse classification, bound cyclin B, activating phosphorylation, and cleared inhibitory sites must coincide for the activity-permissive state. Removing inhibitory phosphate groups does not supply missing cyclin B or activating phosphorylation. Conversely, adding activating phosphorylation does not erase inhibitory modification. Actual preparations contain mixtures of states and additional regulators; this classification gives no numerical reaction rate.
A 2003 study split a Xenopus laevis egg extract into portions with different histories. One received calcium to destroy endogenous cyclin B before receiving nondegradable cyclin B; the other received nondegradable cyclin B first, then calcium. The same sustained cyclin B dose was approached from low or high Cdc2 activity. A phosphorimager quantified histone H1 phosphorylation, sampling every – minutes until an apparent stationary response. At –, the dose maintained high activity but failed to induce it from the low state.[ref]
Controls tracked labeled endogenous cyclin B disappearance after calcium treatment and persistence of nondegradable cyclin B, addressing unequal remaining input. The comparison supports hysteresis under extract conditions; finite observations cannot establish indefinite persistence. It does not isolate each reinforcing path or establish thresholds in intact biological cells.[ref]
Histone H1 2026-10-14
Histone H1 is the protein used as a substrate for the Cdc2 activity readout in the cell-cycle hysteresis experiment.
Histone H1 kinase assay 2026-10-14
A histone H1 kinase assay measures protein kinase action on supplied histone H1, a protein substrate. When the transferred phosphate carries a radioactive isotope label, label incorporated into histone H1 reports catalytic action over the assay interval. It does not count CDK1 molecules, and a crude preparation can contain other protein kinases acting on histone H1. Attribution therefore needs controls.
A 2010 study prepared human HeLa S3 extracts after a double thymidine block, using swelling, a Dounce homogenizer, centrifugation, dialysis and concentration. Added recombinant cyclin B1 incubated for minutes.[ref]
Aliquots received histone H1 and terminal--labeled ATP for a -minute room-temperature reaction, stopped with Laemmli buffer. Dried SDS-PAGE gels exposed a phosphorimager screen; a BioRad Molecular Imager FX quantified labeling. No-added-cyclin B activity set the normalization baseline; RO-3306 reduced H1 activity approximately . Companion Western blots monitored Tyr15 phosphorylation, with actin Western blot loading control.[ref]
Mixed extracts lose compartment boundaries; inhibitor sensitivity supports a major CDK1 contribution, with residual signal.[ref] Substrate choice and inhibitor specificity limit attribution. The cell-cycle hysteresis experiment supplies a separate history comparison with this kind of histone H1 readout; its dose thresholds should not be transferred to human biological cells.
Figure 1.
The histone H1 kinase assay: transferred label, controls and distinct protein measurements
. Original explanatory workflow of the inspected 2010 assay. The -minute extract incubation and -minute assay reaction are separate intervals. No gel lanes or measured intensities are simulated. The no-added-cyclin B baseline and RO-3306 perturbation have different purposes; neither a total-CDK1 Western blot nor a site-specific phosphorylation Western blot replaces the catalytic readout. Details.